Market Analysis
Life Sciences Real Estate: How the AI Biotech Revolution Is Creating a New Institutional Asset Class in 2026
By Abhii Dabas
June 4, 2026
9 min read
Introduction
Life sciences real estate has emerged from a painful two-year correction as one of the most structurally compelling investment theses in global real estate: R&D investment sales rebounded to $13.5 billion in 2025, up 28% year-over-year, while Blackstone's record $6.3 billion life sciences fund close in March 2026 signals institutional conviction that the market has found its floor. The vacancy overhang — 27.4% aggregate across the 10 largest US markets in Q1 2026 — is real but increasingly understood as a supply-cycle artifact rather than a demand collapse: the construction pipeline has fallen to its lowest level since 2017, while AI-driven biotech investment is creating a new generation of laboratory demand that blends wet lab, dry lab, and computational infrastructure in formats the existing building stock cannot adequately provide. For investors willing to underwrite a 24-36 month absorption window, the cluster selectivity is the entire trade — premier assets in Boston's Cambridge submarket, the UK's Golden Triangle, and Singapore's Biopolis sit at the opposite end of the risk spectrum from speculative secondary-market additions that have driven aggregate vacancy figures to misleading highs.
Investment Volume Recovery and the Vacancy Myth
- Investment Volume Recovery: $13.5 Billion and Rising:R&D investment sales across the US rebounded sharply to $13.5 billion in 2025, a 28% year-over-year increase that confirmed the pricing reset from the 2022-2024 downturn had reached a level attractive to institutional buyers. Blackstone reinforced this conviction at scale, closing a record $6.3 billion dedicated life sciences fund in March 2026 — the largest vehicle of its kind in history — targeted at premier cluster assets in Boston, San Diego, and the UK Golden Triangle. Venture capital funding into life sciences companies reached $7.5 billion in Q1 2026 alone, up 12% year-over-year, providing the tenant formation pipeline that underpins longer-term occupier demand. The combination of declining construction activity and accelerating occupier formation points toward a 2027-2028 tightening cycle in premier cluster markets.
- Vacancy Unpacked: Cluster Quality vs Speculative Overhang:The headline vacancy figure of 27.4% across JLL's 10 tracked US markets masks extreme bifurcation. Boston's Cambridge submarket, home to Kendall Square and the MIT innovation ecosystem, recorded 22.9% availability — meaningfully better than the metro average of 28% — because developers there maintained more disciplined pipelines and tenant credit quality is anchored by MIT spin-outs, large pharma partnerships, and AI-biotech hybrids. By contrast, markets that experienced speculative over-building during the 2021 funding frenzy — particularly suburban markets with weaker tenant pools — account for the bulk of the overhang. The strategic signal is in the geography: LA-Orange County, Philadelphia, suburban Maryland, and Denver all maintained vacancy below 20% because supply was constrained relative to demand. Approximately 55.6% of space delivered between 2020 and 2025 in the US is currently vacant, but this figure is concentrated in a small number of over-supplied submarkets rather than distributed evenly.
- Construction Pipeline: Structural Tightening Ahead:The life sciences construction pipeline peaked at 63 million square feet in Q2 2023 — the high watermark of the pandemic-era biotech boom — and has since declined sharply to its lowest level since 2017. Of the approximately 6 million square feet expected to deliver across the US by end of 2026, 63% is already preleased, a ratio that demonstrates the structural shift from speculative development toward build-to-suit and pre-leased projects. Fit-out costs averaging $741 per square foot (down 2.9% year-over-year as construction cost inflation eases) are still creating a high barrier to new development that further constrains supply response. The infrastructure constraint is also real: power availability can delay laboratory occupancy by up to two years in markets requiring electrical grid upgrades, creating a structural advantage for existing purpose-built assets over new entrants.
US Cluster Markets: From Boston Correction to San Diego Resilience
- Boston-Cambridge: Rental Reset Creating Entry Points:Boston's life sciences market accumulated 17 million square feet of available space by Q2 2025 — including sublease space, the figure surges to 29.7% availability — as a combination of speculative over-building and venture-backed company failures created the largest single-market oversupply episode in the sector's history. Average asking rents fell 6% year-over-year to $82.51 per square foot by Q2 2025, breaking below $80 per square foot for the first time since 2022. For patient institutional investors, this represents the entry point: Cambridge's structural advantages are permanent (MIT adjacency, dense talent pool, established pharma campus infrastructure), the pipeline is contracting, and the emerging AI-biotech wave — companies requiring 50/50 blends of computational and wet lab space — is creating demand formats that older buildings cannot serve. The pricing reset is bringing cap rates back to levels that can underwrite a reasonable forward return, which is precisely why Blackstone committed $6.3 billion to the cycle.
- San Diego: Diversified Demand Drives Resilience:San Diego stands apart from the Boston correction narrative with a more diversified tenant base across genomics, therapeutics, medical devices, and defense biotech that has insulated occupancy from the pure venture capital dependency that proved fragile in Massachusetts. Occupancy remained above comparable national averages through the correction, supported by the established presence of major pharmaceutical operators including Pfizer, AstraZeneca, and Illumina. The Torrey Pines and Sorrento Valley submarkets command rents in the $70-85 per square foot range for premium space, with limited new speculative supply scheduled for 2026, positioning San Diego as the most immediately investable US cluster for income-focused strategies relative to the higher-volatility Boston market.
UK Golden Triangle and Asia-Pacific: Where the Pipeline Is Tightest
- UK Golden Triangle: Europe's Strongest Momentum:The UK's London-Oxford-Cambridge corridor delivered the strongest life sciences real estate performance data globally in Q1 2026: take-up across the Golden Triangle reached 457,000 square feet, 35% above the five-year average, with Cambridge alone recording 298,000 square feet of major tenant transactions including NVIDIA, Huawei, and Aveva. Prime quoting rents held firm: Oxford at £70 per square foot, Cambridge at £77 per square foot, and London's knowledge quarter at £140 per square foot. The 3.7 million square foot construction pipeline, with 42.9% expected for 2026 delivery, is among the tightest relative to demand of any global cluster. The government's Life Sciences Vision commitment to making the UK a world-leading life sciences hub is backed by planning reforms that prioritise lab space in the Cambridge cluster, creating a regulatory tailwind that is structurally different from the US market.
- Singapore and Zurich: Asia-Pacific and European Entry Points:Singapore's Geneo hub, opened in May 2026 by CapitaLand, represents the most significant life sciences real estate development in Asia-Pacific: a S$1.4 billion ($1.09 billion) facility spanning 180,600 square metres at Singapore Science Park, adjacent to the established Biopolis precinct where occupancy has remained at 95%. CapitaLand Ascendas REIT's approximately 4.5 million square feet at Singapore Science Park provides listed investors access to the precinct's pricing power, underpinned by Singapore's S$37 billion RIE 2030 research commitment. Zurich offers the most attractive European entry point on a relative value basis: European life sciences properties trade approximately 40% below equivalent US assets, and Schroder ImmoPLUS demonstrated the viability of the European market with a CHF 170 million Swiss deal on a 25-year life sciences lease at a 4% net yield — a risk-adjusted return profile that would be difficult to achieve in any comparable US cluster. Asia-Pacific's life sciences real estate market is on an accelerating trajectory: valued at $3.75 billion in 2025, it is projected to reach $6.76 billion by 2034 at a 6.76% CAGR, the highest growth rate of any global region.
AI Biotech and the Patent Cliff: New Demand Formats Reshaping the Market
- AI Biotech: A Demand Driver That Rewrites Space Requirements:The AI in biotechnology market is projected to expand from $4.16 billion in 2025 to $22.72 billion by 2035 — a 5.5x growth that is generating a new cohort of occupiers whose space requirements differ materially from traditional pharmaceutical tenants. AI-driven biotech companies need a 50/50 blend of computational infrastructure (high-density power, cooling, structured cabling) and wet laboratory space for biological validation, a combination that the speculative 2020-2023 wave of generic lab buildings — built for pure wet lab occupiers — cannot deliver. This mismatch is the latent opportunity: investors acquiring purpose-built facilities capable of supporting hybrid AI-biotech tenants in premier clusters are acquiring assets that existing supply cannot replicate, creating pricing power that underpins rent growth even in markets with elevated aggregate vacancy. Biotech employment reached a record high after five consecutive months of expansion as of early 2026, confirming that the sector's talent demand — and therefore its real estate demand — is growing even as the venture capital cycle normalises.
- Pharmaceutical M&A and Patent Cliff as Demand Catalysts:The life sciences sector entered 2025-2026 with a structural demand accelerant: the "patent cliff," the wave of major drug patent expirations scheduled through 2030 that is forcing Big Pharma to accelerate external R&D through acquisitions, licensing deals, and campus expansions near key innovation clusters. AstraZeneca, Pfizer, Eli Lilly, and Merck all announced expanded campus requirements in Boston, San Diego, or London through 2025-2026, driven by the need to replenish drug pipelines under the dual pressure of patent expiries and post-pandemic revenue normalisation. This M&A-driven demand is categorically different from venture-backed startup demand: it is credit-backed, long-term lease-eligible, and creates the anchor tenancy that makes speculative development risk underwritable again in premier cluster markets.
Risks: Concentration, Tenant Credit, and Regulatory Exposure
- Cluster Concentration Risk and Secondary Market Exposure:The structural risks in life sciences real estate are real and largely geographic: performance is concentrated in four to five premier clusters globally, and investors who diverge from Boston, San Diego, San Francisco, London's Golden Triangle, and Singapore's Biopolis precinct into secondary markets face extended vacancy cycles that can outlast conventional underwriting assumptions. Approximately 55.6% of space delivered in the US between 2020 and 2025 is currently vacant, and the distribution is heavily skewed toward secondary suburban markets. Tenant credit risk from venture-backed occupiers — particularly early-stage pre-revenue biotech companies that represent the most common life sciences lease counterparty — remains elevated as the VC funding cycle normalises from 2021 peak levels, with some subtenants subleasing excess space that has contributed materially to the aggregate availability figures.
- Regulatory and Funding Environment:Uncertainty around US government biomedical research funding — particularly through the National Institutes of Health and BARDA — creates a tail risk for the demand side of life sciences real estate that is different from any other commercial real estate sector. Funding policy changes can affect the formation rate of university spin-outs and early-stage companies that represent the bottom of the tenant formation pipeline. The UK's post-Brexit access to EU research programs under Horizon Europe association provides comparative regulatory certainty that is contributing to the Golden Triangle's outperformance relative to continental European life sciences clusters. Investors with meaningful US life sciences exposure should maintain awareness of federal research budget cycles as a leading indicator of occupier demand, particularly in university-adjacent cluster markets.
Investment Strategy: Cluster First, Format Second, Timing Third
- Cluster Selectivity: The Entire Investment Trade:For institutional capital seeking life sciences real estate exposure in 2026, cluster selectivity is the primary investment decision — everything else is secondary. Boston's Cambridge submarket, San Diego's Torrey Pines and Sorrento Valley, the UK Golden Triangle (Cambridge, Oxford, London knowledge quarter), and Singapore's Biopolis precinct are the five markets where supply is tight, tenant formation is anchored by world-class research institutions, and rental growth trajectories are credible over a five-to-seven year hold. Secondary US markets with elevated vacancy and weak venture ecosystems require either deep local expertise or an acceptance of a value-add positioning risk that most institutional mandates cannot accommodate.
- Asia-Pacific: Growth Premium at Attractive Valuations:For investors who can access Asia-Pacific exposure, Singapore and the emerging Shanghai biomedical cluster offer the highest growth trajectory at valuations below comparable US assets. Singapore's Biopolis provides listed access via CapitaLand Ascendas REIT; Shanghai's biomedical cluster in Zhangjiang added 3.5 million square feet in 2023 and is continuing to attract both domestic and international life sciences tenants with government incentives that include subsidised land, tax concessions, and infrastructure grants. The 6.76% CAGR to 2034 for Asia-Pacific life sciences real estate is the highest regional growth rate globally, reflecting both the depth of government commitment to building biomedical clusters and the early-stage nature of cluster formation that provides longer runways for capital appreciation than the more mature North American and UK markets.
- Europe as Value Play: Zurich and the Golden Triangle:European life sciences real estate — trading at approximately 40% below equivalent US assets — represents the best relative value in the global sector for investors who can accept lower growth rates in exchange for lower entry costs and more predictable regulatory environments. The UK Golden Triangle offers the highest growth and tightest supply of any European cluster; Zurich offers institutional-quality infrastructure at yields (4% net on 25-year leases) that are credible risk-adjusted returns for long-duration capital. Continental European markets including Munich, Amsterdam, and Copenhagen are developing secondary clusters that may warrant watch-list exposure, but lack the critical mass of talent, capital, and institutional anchor tenancies that define a tier-one cluster and justify speculative development risk.
This content is AI-generated and may contain errors. Figures are indicative and subject to change. Do your own due diligence and seek independent legal and financial advice.
Sources
- CBRE — U.S. Real Estate Market Outlook 2026: Life Sciences
- JLL — Life Sciences Real Estate Outlook 2025
- CBRE — 2026 U.S. Life Sciences Trends
- CBRE UK — Life Sciences Outlook 2026
- Mingtiandi — CapitaLand Opens S$1.4B Geneo Life Sciences Hub
- Cushman & Wakefield — Life Sciences Sector Enters Measured Growth Phase
- CBRE Asia Pacific — A New Era of Life Sciences Growth
- JLL — Lab Market Faces Unprecedented Tenant Advantage
- Cushman & Wakefield — Life Sciences Fit Out Cost Guide
Author
Abhii DabasFounder & CEO, INTRIC Global
Abhii Dabas is the Founder and CEO of INTRIC Global, the cross-border property intelligence platform for serious investors. He advises high-net-worth buyers on international real estate strategy and has evaluated residential markets across more than 40 countries.
Share
Share this article with others
Introduction
Life sciences real estate has emerged from a painful two-year correction as one of the most structurally compelling investment theses in global real estate: R&D investment sales rebounded to $13.5 billion in 2025, up 28% year-over-year, while Blackstone's record $6.3 billion life sciences fund close in March 2026 signals institutional conviction that the market has found its floor. The vacancy overhang — 27.4% aggregate across the 10 largest US markets in Q1 2026 — is real but increasingly understood as a supply-cycle artifact rather than a demand collapse: the construction pipeline has fallen to its lowest level since 2017, while AI-driven biotech investment is creating a new generation of laboratory demand that blends wet lab, dry lab, and computational infrastructure in formats the existing building stock cannot adequately provide. For investors willing to underwrite a 24-36 month absorption window, the cluster selectivity is the entire trade — premier assets in Boston's Cambridge submarket, the UK's Golden Triangle, and Singapore's Biopolis sit at the opposite end of the risk spectrum from speculative secondary-market additions that have driven aggregate vacancy figures to misleading highs.
Investment Volume Recovery and the Vacancy Myth
- Investment Volume Recovery: $13.5 Billion and Rising:R&D investment sales across the US rebounded sharply to $13.5 billion in 2025, a 28% year-over-year increase that confirmed the pricing reset from the 2022-2024 downturn had reached a level attractive to institutional buyers. Blackstone reinforced this conviction at scale, closing a record $6.3 billion dedicated life sciences fund in March 2026 — the largest vehicle of its kind in history — targeted at premier cluster assets in Boston, San Diego, and the UK Golden Triangle. Venture capital funding into life sciences companies reached $7.5 billion in Q1 2026 alone, up 12% year-over-year, providing the tenant formation pipeline that underpins longer-term occupier demand. The combination of declining construction activity and accelerating occupier formation points toward a 2027-2028 tightening cycle in premier cluster markets.
- Vacancy Unpacked: Cluster Quality vs Speculative Overhang:The headline vacancy figure of 27.4% across JLL's 10 tracked US markets masks extreme bifurcation. Boston's Cambridge submarket, home to Kendall Square and the MIT innovation ecosystem, recorded 22.9% availability — meaningfully better than the metro average of 28% — because developers there maintained more disciplined pipelines and tenant credit quality is anchored by MIT spin-outs, large pharma partnerships, and AI-biotech hybrids. By contrast, markets that experienced speculative over-building during the 2021 funding frenzy — particularly suburban markets with weaker tenant pools — account for the bulk of the overhang. The strategic signal is in the geography: LA-Orange County, Philadelphia, suburban Maryland, and Denver all maintained vacancy below 20% because supply was constrained relative to demand. Approximately 55.6% of space delivered between 2020 and 2025 in the US is currently vacant, but this figure is concentrated in a small number of over-supplied submarkets rather than distributed evenly.
- Construction Pipeline: Structural Tightening Ahead:The life sciences construction pipeline peaked at 63 million square feet in Q2 2023 — the high watermark of the pandemic-era biotech boom — and has since declined sharply to its lowest level since 2017. Of the approximately 6 million square feet expected to deliver across the US by end of 2026, 63% is already preleased, a ratio that demonstrates the structural shift from speculative development toward build-to-suit and pre-leased projects. Fit-out costs averaging $741 per square foot (down 2.9% year-over-year as construction cost inflation eases) are still creating a high barrier to new development that further constrains supply response. The infrastructure constraint is also real: power availability can delay laboratory occupancy by up to two years in markets requiring electrical grid upgrades, creating a structural advantage for existing purpose-built assets over new entrants.
US Cluster Markets: From Boston Correction to San Diego Resilience
- Boston-Cambridge: Rental Reset Creating Entry Points:Boston's life sciences market accumulated 17 million square feet of available space by Q2 2025 — including sublease space, the figure surges to 29.7% availability — as a combination of speculative over-building and venture-backed company failures created the largest single-market oversupply episode in the sector's history. Average asking rents fell 6% year-over-year to $82.51 per square foot by Q2 2025, breaking below $80 per square foot for the first time since 2022. For patient institutional investors, this represents the entry point: Cambridge's structural advantages are permanent (MIT adjacency, dense talent pool, established pharma campus infrastructure), the pipeline is contracting, and the emerging AI-biotech wave — companies requiring 50/50 blends of computational and wet lab space — is creating demand formats that older buildings cannot serve. The pricing reset is bringing cap rates back to levels that can underwrite a reasonable forward return, which is precisely why Blackstone committed $6.3 billion to the cycle.
- San Diego: Diversified Demand Drives Resilience:San Diego stands apart from the Boston correction narrative with a more diversified tenant base across genomics, therapeutics, medical devices, and defense biotech that has insulated occupancy from the pure venture capital dependency that proved fragile in Massachusetts. Occupancy remained above comparable national averages through the correction, supported by the established presence of major pharmaceutical operators including Pfizer, AstraZeneca, and Illumina. The Torrey Pines and Sorrento Valley submarkets command rents in the $70-85 per square foot range for premium space, with limited new speculative supply scheduled for 2026, positioning San Diego as the most immediately investable US cluster for income-focused strategies relative to the higher-volatility Boston market.
UK Golden Triangle and Asia-Pacific: Where the Pipeline Is Tightest
- UK Golden Triangle: Europe's Strongest Momentum:The UK's London-Oxford-Cambridge corridor delivered the strongest life sciences real estate performance data globally in Q1 2026: take-up across the Golden Triangle reached 457,000 square feet, 35% above the five-year average, with Cambridge alone recording 298,000 square feet of major tenant transactions including NVIDIA, Huawei, and Aveva. Prime quoting rents held firm: Oxford at £70 per square foot, Cambridge at £77 per square foot, and London's knowledge quarter at £140 per square foot. The 3.7 million square foot construction pipeline, with 42.9% expected for 2026 delivery, is among the tightest relative to demand of any global cluster. The government's Life Sciences Vision commitment to making the UK a world-leading life sciences hub is backed by planning reforms that prioritise lab space in the Cambridge cluster, creating a regulatory tailwind that is structurally different from the US market.
- Singapore and Zurich: Asia-Pacific and European Entry Points:Singapore's Geneo hub, opened in May 2026 by CapitaLand, represents the most significant life sciences real estate development in Asia-Pacific: a S$1.4 billion ($1.09 billion) facility spanning 180,600 square metres at Singapore Science Park, adjacent to the established Biopolis precinct where occupancy has remained at 95%. CapitaLand Ascendas REIT's approximately 4.5 million square feet at Singapore Science Park provides listed investors access to the precinct's pricing power, underpinned by Singapore's S$37 billion RIE 2030 research commitment. Zurich offers the most attractive European entry point on a relative value basis: European life sciences properties trade approximately 40% below equivalent US assets, and Schroder ImmoPLUS demonstrated the viability of the European market with a CHF 170 million Swiss deal on a 25-year life sciences lease at a 4% net yield — a risk-adjusted return profile that would be difficult to achieve in any comparable US cluster. Asia-Pacific's life sciences real estate market is on an accelerating trajectory: valued at $3.75 billion in 2025, it is projected to reach $6.76 billion by 2034 at a 6.76% CAGR, the highest growth rate of any global region.
AI Biotech and the Patent Cliff: New Demand Formats Reshaping the Market
- AI Biotech: A Demand Driver That Rewrites Space Requirements:The AI in biotechnology market is projected to expand from $4.16 billion in 2025 to $22.72 billion by 2035 — a 5.5x growth that is generating a new cohort of occupiers whose space requirements differ materially from traditional pharmaceutical tenants. AI-driven biotech companies need a 50/50 blend of computational infrastructure (high-density power, cooling, structured cabling) and wet laboratory space for biological validation, a combination that the speculative 2020-2023 wave of generic lab buildings — built for pure wet lab occupiers — cannot deliver. This mismatch is the latent opportunity: investors acquiring purpose-built facilities capable of supporting hybrid AI-biotech tenants in premier clusters are acquiring assets that existing supply cannot replicate, creating pricing power that underpins rent growth even in markets with elevated aggregate vacancy. Biotech employment reached a record high after five consecutive months of expansion as of early 2026, confirming that the sector's talent demand — and therefore its real estate demand — is growing even as the venture capital cycle normalises.
- Pharmaceutical M&A and Patent Cliff as Demand Catalysts:The life sciences sector entered 2025-2026 with a structural demand accelerant: the "patent cliff," the wave of major drug patent expirations scheduled through 2030 that is forcing Big Pharma to accelerate external R&D through acquisitions, licensing deals, and campus expansions near key innovation clusters. AstraZeneca, Pfizer, Eli Lilly, and Merck all announced expanded campus requirements in Boston, San Diego, or London through 2025-2026, driven by the need to replenish drug pipelines under the dual pressure of patent expiries and post-pandemic revenue normalisation. This M&A-driven demand is categorically different from venture-backed startup demand: it is credit-backed, long-term lease-eligible, and creates the anchor tenancy that makes speculative development risk underwritable again in premier cluster markets.
Risks: Concentration, Tenant Credit, and Regulatory Exposure
- Cluster Concentration Risk and Secondary Market Exposure:The structural risks in life sciences real estate are real and largely geographic: performance is concentrated in four to five premier clusters globally, and investors who diverge from Boston, San Diego, San Francisco, London's Golden Triangle, and Singapore's Biopolis precinct into secondary markets face extended vacancy cycles that can outlast conventional underwriting assumptions. Approximately 55.6% of space delivered in the US between 2020 and 2025 is currently vacant, and the distribution is heavily skewed toward secondary suburban markets. Tenant credit risk from venture-backed occupiers — particularly early-stage pre-revenue biotech companies that represent the most common life sciences lease counterparty — remains elevated as the VC funding cycle normalises from 2021 peak levels, with some subtenants subleasing excess space that has contributed materially to the aggregate availability figures.
- Regulatory and Funding Environment:Uncertainty around US government biomedical research funding — particularly through the National Institutes of Health and BARDA — creates a tail risk for the demand side of life sciences real estate that is different from any other commercial real estate sector. Funding policy changes can affect the formation rate of university spin-outs and early-stage companies that represent the bottom of the tenant formation pipeline. The UK's post-Brexit access to EU research programs under Horizon Europe association provides comparative regulatory certainty that is contributing to the Golden Triangle's outperformance relative to continental European life sciences clusters. Investors with meaningful US life sciences exposure should maintain awareness of federal research budget cycles as a leading indicator of occupier demand, particularly in university-adjacent cluster markets.
Investment Strategy: Cluster First, Format Second, Timing Third
- Cluster Selectivity: The Entire Investment Trade:For institutional capital seeking life sciences real estate exposure in 2026, cluster selectivity is the primary investment decision — everything else is secondary. Boston's Cambridge submarket, San Diego's Torrey Pines and Sorrento Valley, the UK Golden Triangle (Cambridge, Oxford, London knowledge quarter), and Singapore's Biopolis precinct are the five markets where supply is tight, tenant formation is anchored by world-class research institutions, and rental growth trajectories are credible over a five-to-seven year hold. Secondary US markets with elevated vacancy and weak venture ecosystems require either deep local expertise or an acceptance of a value-add positioning risk that most institutional mandates cannot accommodate.
- Asia-Pacific: Growth Premium at Attractive Valuations:For investors who can access Asia-Pacific exposure, Singapore and the emerging Shanghai biomedical cluster offer the highest growth trajectory at valuations below comparable US assets. Singapore's Biopolis provides listed access via CapitaLand Ascendas REIT; Shanghai's biomedical cluster in Zhangjiang added 3.5 million square feet in 2023 and is continuing to attract both domestic and international life sciences tenants with government incentives that include subsidised land, tax concessions, and infrastructure grants. The 6.76% CAGR to 2034 for Asia-Pacific life sciences real estate is the highest regional growth rate globally, reflecting both the depth of government commitment to building biomedical clusters and the early-stage nature of cluster formation that provides longer runways for capital appreciation than the more mature North American and UK markets.
- Europe as Value Play: Zurich and the Golden Triangle:European life sciences real estate — trading at approximately 40% below equivalent US assets — represents the best relative value in the global sector for investors who can accept lower growth rates in exchange for lower entry costs and more predictable regulatory environments. The UK Golden Triangle offers the highest growth and tightest supply of any European cluster; Zurich offers institutional-quality infrastructure at yields (4% net on 25-year leases) that are credible risk-adjusted returns for long-duration capital. Continental European markets including Munich, Amsterdam, and Copenhagen are developing secondary clusters that may warrant watch-list exposure, but lack the critical mass of talent, capital, and institutional anchor tenancies that define a tier-one cluster and justify speculative development risk.
This content is AI-generated and may contain errors. Figures are indicative and subject to change. Do your own due diligence and seek independent legal and financial advice.
Sources
- CBRE — U.S. Real Estate Market Outlook 2026: Life Sciences
- JLL — Life Sciences Real Estate Outlook 2025
- CBRE — 2026 U.S. Life Sciences Trends
- CBRE UK — Life Sciences Outlook 2026
- Mingtiandi — CapitaLand Opens S$1.4B Geneo Life Sciences Hub
- Cushman & Wakefield — Life Sciences Sector Enters Measured Growth Phase
- CBRE Asia Pacific — A New Era of Life Sciences Growth
- JLL — Lab Market Faces Unprecedented Tenant Advantage
- Cushman & Wakefield — Life Sciences Fit Out Cost Guide
Author
Abhii DabasFounder & CEO, INTRIC Global
Abhii Dabas is the Founder and CEO of INTRIC Global, the cross-border property intelligence platform for serious investors. He advises high-net-worth buyers on international real estate strategy and has evaluated residential markets across more than 40 countries.
Share this article
Share this insight with others
Share
Share this article with others
Related Market Insights
View More Market Insights
Market Analysis
China's 35-Month Decline and Hong Kong's Recovery: Why "China Property" Is Not One Trade
By Abhii Dabas · July 10, 2026
Market Analysis
Nordic Real Estate in 2026: Record Institutional Capital Meets Europe's Worst Housing Shortage
By Abhii Dabas · June 25, 2026
Market Analysis
Spain and Iberia in 2026: Europe's Top Investment Market Navigates a Housing Paradox
By Abhii Dabas · June 25, 2026
Found this useful? Send it to someone who should read it.
Share
Continue with INTRIC
